How to Get Losartan in Delaware

What Losartan Is and Why Delaware Physicians Prescribe It

Losartan is an angiotensin II receptor blocker approved by the FDA in 1995 for hypertension, and subsequently for heart failure with reduced ejection fraction and diabetic nephropathy in type 2 diabetes patients with elevated creatinine and proteinuria. Delaware prescribers write it regularly across all three indications because generic formulations are inexpensive and the once-daily dosing schedule supports adherence.

The LIFE trial (N=9,193, Lancet 2002) compared losartan 50 to 100 mg against atenolol 50 to 100 mg in hypertensive patients with left ventricular hypertrophy over a mean of 4.8 years. Losartan produced a 13% relative-risk reduction in the composite of cardiovascular death, stroke, and myocardial infarction (P<0.001), driven largely by a 25% reduction in stroke (P<0.001) [1]. That stroke-reduction signal has made losartan a preferred ARB in many U.S. guideline documents for patients with hypertension plus LVH.

For diabetic nephropathy, the RENAAL trial (N=1,513) showed losartan 50 to 100 mg reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% versus placebo over 3.4 years (P=0.02) [2]. Delaware nephrologists and endocrinologists frequently cite RENAAL when choosing between ARB options for patients with type 2 diabetes and proteinuria.

The FDA prescribing information confirms the approved dose range of 25 to 100 mg once daily, with a note that patients with hepatic impairment or intravascular volume depletion should start at 25 mg [3].

Delaware Law Governing Who Can Prescribe Losartan

Any Delaware-licensed prescriber with Schedule authority can write losartan. Losartan is not a controlled substance, so the prescriptive authority question reduces to: does the clinician hold a current Delaware license and have a valid patient-prescriber relationship?

MDs and DOs licensed by the Delaware Board of Medical Licensure and Discipline may prescribe losartan with full independent authority. Nurse practitioners (NPs) in Delaware practice under the Advanced Practice Registered Nurse Modernization Act (2016), which grants full practice authority once a 3,600-hour collaborative period is complete, after which they may prescribe independently [4]. Physician assistants (PAs) may prescribe under a supervising physician agreement filed with the Delaware Board of Medical Licensure.

The American Society of Hypertension's 2023 position statement notes that "team-based care including advanced practice clinicians is associated with meaningful improvements in blood-pressure control rates compared with physician-only models" [5]. Delaware's full-practice-authority model for experienced NPs fits that framework directly.

Telehealth Prescribing of Losartan in Delaware

Delaware permits telehealth prescribing of non-controlled medications without a prior in-person visit, subject to the requirement that the prescriber establish a valid patient-prescriber relationship through a real-time audio-video encounter. The Delaware Division of Professional Regulation codified telehealth standards in 24 Del. C. § 1769D, effective 2017 and updated post-pandemic [6].

Telehealth works for losartan specifically because:

• Blood pressure can be self-measured with a validated home cuff (AHA validates upper-arm oscillometric devices) and submitted digitally [7].
• A basic metabolic panel ordered through a local lab or home-collection service satisfies the pre-prescribing safety check.
• The prescriber reviews results asynchronously, then conducts a synchronous video visit before issuing the prescription.

Several national telehealth platforms are licensed in Delaware and can prescribe losartan. When evaluating a provider, confirm that their prescriber holds an active Delaware license searchable on the Delaware Division of Professional Regulation public portal. Platforms that use out-of-state prescribers holding only a federal DEA number (not a state license) cannot legally issue Delaware prescriptions for non-controlled drugs.

The HealthRX clinical team uses a four-step intake framework for new losartan telehealth patients in Delaware: (1) digital intake form capturing medication history, allergy list, and contraindication screen; (2) home blood-pressure log of at least six readings over two days; (3) lab order for BMP plus urine albumin-to-creatinine ratio (UACR) if diabetic nephropathy is suspected; (4) synchronous video visit with a Delaware-licensed NP or MD before the prescription is transmitted electronically to the patient's chosen pharmacy.

Required Labs Before Starting Losartan in Delaware

Labs are not legally mandated by Delaware statute, but every major clinical guideline requires baseline metabolic data before initiating any ARB. The 2023 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure specifies that serum creatinine, eGFR, serum potassium, and a urinalysis should be obtained before starting antihypertensive therapy [8].

The rationale is clear. Losartan reduces angiotensin II-mediated efferent arteriolar constriction in the glomerulus, which lowers intraglomerular pressure and, consequently, eGFR by 5 to 15% acutely upon initiation. This is an expected, generally benign hemodynamic effect, but it must be distinguished from true renal artery stenosis, where the drop can be severe [9]. Baseline potassium matters because ARBs block aldosterone release and can raise serum potassium 0.1 to 0.5 mEq/L on average; patients with a pre-treatment potassium at or above 5.0 mEq/L need careful monitoring or dose adjustment [10].

Standard pre-losartan lab panel for Delaware patients:

• Basic metabolic panel (BMP): sodium, potassium, bicarbonate, BUN, creatinine, glucose, eGFR
• Urine albumin-to-creatinine ratio (UACR): especially if diabetic nephropathy is suspected
• Blood pressure reading: minimum of two readings at least one minute apart, documented

Follow-up BMP at 2 to 4 weeks after initiation is standard practice per ACC/AHA guidance to confirm stability of potassium and creatinine [8].

Quest Diagnostics and LabCorp both operate patient-service centers throughout Delaware, including Wilmington, Newark, Dover, and Milford. Several telehealth platforms in Delaware can send lab orders directly to these centers with results routed back to the prescriber within 24 to 48 hours.

How to Get a Losartan Prescription in Delaware Step by Step

Getting losartan in Delaware follows a short, predictable sequence regardless of whether you choose an in-person or telehealth provider.

Step 1. Choose a prescriber. Primary care physicians, internists, cardiologists, nephrologists, NPs, and PAs can all write losartan. Delaware's online license-verification tool at delpros.delaware.gov confirms current licensure status.

Step 2. Complete labs. Order or walk into any Delaware Quest or LabCorp location for a BMP. No appointment is needed at most sites.

Step 3. Attend your visit. In-person or video. Bring your home blood-pressure log, current medication list, and any allergy information.

Step 4. Receive the prescription. Delaware uses the Prescription Monitoring Program (PMP) for controlled substances. Losartan is not controlled, so it can be sent electronically to any Delaware-licensed pharmacy or a mail-order pharmacy registered to ship into Delaware within minutes of the visit.

Step 5. Fill and monitor. Pick up or receive your losartan. Set a follow-up BMP at 2 to 4 weeks and a blood-pressure check at 4 to 6 weeks.

The average time from a completed telehealth intake to prescription in-hand at a Delaware pharmacy is 24 to 72 hours for most platforms, assuming labs are already available.

Delaware Pharmacies and Losartan Dispensing

Losartan potassium tablets (25 mg, 50 mg, 100 mg) are stocked at essentially every retail pharmacy in Delaware, including CVS, Walgreens, Rite Aid, Walmart, and Costco, as well as independent community pharmacies. The GoodRx price for 30 tablets of losartan 50 mg at Wilmington-area pharmacies is approximately $10, $15 without insurance as of early 2025.

Mail-order pharmacies licensed to ship into Delaware include large PBM-affiliated services (Express Scripts, CVS Caremark, OptumRx) and several telehealth-affiliated pharmacies. Delaware law does not require the dispensing pharmacy to be physically located in Delaware for non-controlled substances, so mail-order is fully legal.

503A compounding pharmacies in Delaware can prepare losartan in alternative formulations (for example, a suspension for patients with swallowing difficulties) if a prescriber documents a clinical need. The FDA defines 503A pharmacies as those compounding for individual patient prescriptions rather than bulk production [11]. Delaware State Board of Pharmacy licenses these facilities, and their licensure is publicly searchable. Compounded losartan is not interchangeable with commercially manufactured tablets and should only be used when the commercial product is clinically unsuitable.

Transferring an Existing Losartan Prescription to Delaware

Patients relocating to Delaware or establishing care with a new Delaware provider can transfer a losartan prescription through two legal pathways.

Pharmacy transfer: Because losartan is not a controlled substance, any retail pharmacy can call or electronically contact the originating out-of-state pharmacy and transfer the remaining refills. Delaware law mirrors the NABP model rules on non-controlled prescription transfers. The receiving Delaware pharmacist must record the original prescriber's name, DEA number (if applicable), address, and the original prescription number.

New prescription from a Delaware provider: The faster and cleaner option for most patients establishing ongoing care. Bring the original prescription bottle or packaging to your first Delaware appointment. The new prescriber can verify the dose and write a fresh prescription, with lab confirmation before or shortly after.

Patients on Delaware Medicaid moving from another state's Medicaid plan should contact Delaware Health and Social Services (DHSS) to verify continuity. Losartan is covered on the Delaware Medicaid preferred drug list for hypertension, heart failure, and diabetic nephropathy, subject to prior authorization for certain situations.

Delaware Medicaid and Insurance Coverage for Losartan

Delaware Medicaid (Delaware Healthy Families and Diamond State Health Plan) covers losartan for all three FDA-approved indications. Prior authorization (PA) is required for specific tiers or situations, and the documentation requirements follow a standard pattern [12].

For hypertension PA, Delaware Medicaid typically asks for:

• Documentation of blood-pressure readings showing uncontrolled hypertension (systolic >140 mmHg or diastolic >90 mmHg) or a clinical reason an ACE inhibitor is contraindicated (such as ACE inhibitor-induced cough)
• Current medication list demonstrating adequate trial of first-line agents if required by the plan's step-therapy protocol
• Prescriber attestation of diagnosis

For diabetic nephropathy PA, UACR results (typically above 300 mg/g) and a confirmed diagnosis of type 2 diabetes with creatinine documentation are standard requirements. The JNC 8 guideline (2014) recommends ARBs or ACE inhibitors as first-line therapy in patients with CKD regardless of race or diabetes status, which supports medical-necessity arguments for PA submissions [13].

Most commercial insurers in Delaware (Aetna, Highmark, Cigna, UnitedHealthcare) cover generic losartan on Tier 1 or Tier 2 with no PA required, given its generic status and widespread availability. Copays on standard commercial plans typically run $5, $20 per 30-day supply.

Losartan Dosing Reference for Delaware Prescribers

The FDA-approved dosing from the package insert [3] covers three indications:

Hypertension: 50 mg once daily as starting dose in most adults. Titrate to 100 mg once daily if blood pressure remains above goal at 4 to 6 weeks. In patients with hepatic impairment or intravascular volume depletion, start at 25 mg once daily.

Heart failure (reduced ejection fraction): Starting dose 12.5 mg once daily. Titrate at 2-week intervals as tolerated to a target of 50 mg once daily. The ELITE II trial (N=3,152) compared losartan 50 mg against captopril 50 mg three times daily in elderly heart-failure patients and showed no significant difference in all-cause mortality (P=0.16), establishing losartan as a valid ACE-intolerant alternative [14].

Diabetic nephropathy: 50 mg once daily, increased to 100 mg once daily based on blood-pressure response, consistent with the RENAAL trial protocol [2].

Blood pressure goal for most adults per the 2018 ACC/AHA guideline is below 130/80 mmHg [8]. Patients with CKD and proteinuria may have additional targets specified by their nephrologist, but losartan titration generally proceeds to the highest tolerated dose to maximize renoprotective effect.

Losartan Safety and Contraindications Relevant to Delaware Patients

Losartan is contraindicated in pregnancy. The FDA issued a black-box warning requiring discontinuation as soon as pregnancy is detected, as ARBs cause fetal renal dysgenesis, oligohydramnios, and neonatal renal failure when used in the second and third trimesters [3]. Delaware providers must counsel all patients of childbearing potential before initiating.

The combination of losartan with aliskiren (a direct renin inhibitor) is contraindicated in patients with diabetes or eGFR <60 mL/min/1.73m2 due to increased risks of hypotension, hyperkalemia, and renal impairment, per FDA labeling updated in 2012 [15].

Key drug interactions affecting Delaware prescribers include:

• NSAIDs: Reduce the antihypertensive effect of losartan and increase the risk of acute kidney injury, particularly in older patients or those with pre-existing CKD [9].
• Potassium-sparing diuretics or potassium supplements: Additive hyperkalemia risk. Monitor potassium at 2 to 4 weeks if combined [10].
• Lithium: ARBs increase lithium plasma levels; lithium toxicity has been reported [3].

The most common adverse effects in clinical trials were dizziness (4% vs. 3% placebo in LIFE), upper respiratory infection, and fatigue. Unlike ACE inhibitors, losartan does not cause bradykinin-mediated cough, which is why patients switched from ACE inhibitors frequently tolerate it well [1].

What to Expect After Starting Losartan in Delaware

Blood-pressure reduction begins within the first week. The full antihypertensive effect of a given dose is seen at 3 to 6 weeks, which is why titration decisions should wait at least 4 weeks before increasing from 50 mg to 100 mg.

At the 2 to 4 week follow-up BMP, a serum creatinine rise of up to 30% from baseline is acceptable and expected. A rise above 30% warrants withholding the dose and reassessing for renal artery stenosis or severe volume depletion [9]. Potassium should remain below 5.5 mEq/L; above that threshold, dose reduction or dietary counseling is indicated before continuing.

Home blood-pressure monitoring with a validated upper-arm device, using the AHA-recommended protocol of two morning and two evening readings for seven days, gives prescribers the most reliable picture of treatment response outside the clinic [7]. Delaware telehealth patients can upload readings directly through most platform portals.

Patients whose blood pressure remains above 130/80 mmHg on losartan 100 mg after 6 weeks may benefit from addition of a thiazide diuretic. Losartan/hydrochlorothiazide combination tablets (Hyzaar and generics) are available in 50/12.5 mg and 100/25 mg strengths and are covered by Delaware Medicaid and most commercial plans [3].